trial
as of 2026-07-01Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia
NCTId NCT01850953
at a glance
Phase 4 · Completed
Enrollment 28 (actual)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2015-05
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
28 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2013-06
Primary completion
2015-05
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Drugs
Sponsors
Centre for Addiction and Mental HealthLead Sponsor
Investigators
1
Tony P George, M.D.Study Director
Sites
1 total
Toronto, Canada
Facts & assertions
4 sourced
Enrollment
28
Phase
PHASE4
Primary Completion Date
2015-05
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
investigator
person